Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials

2023136 citationsJournal Articlehybrid Open Access

Authors

Xinan Sheng · Peking University

Lin Wang · Chinese Academy of Medical Sciences & Peking Union Medical College

Zhisong He · Peking University

Yanxia Shi · Sun Yat-sen University

Hong Luo · Chongqing University

Weiqing Han · Central South University

Xin Yao ·

Abstract

DV demonstrated a promising efficacy with a manageable safety profile in patients with HER2-positive locally advanced or metastatic UC who had progressed on at least one line of systemic chemotherapy.

Topics & Keywords

Bladder and Urothelial Cancer Treatments Esophageal Cancer Research and Treatment Gastric Cancer Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 42, Issue 12, pp. 1391-1402

DOI: 10.1200/jco.22.02912

Field-Weighted Citation Impact: 42.58